as 11-12-2024 4:00pm EST
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
Founded: | 2020 | Country: | United Kingdom |
Employees: | N/A | City: | ALTRINCHAM, CHESHIRE |
Market Cap: | 2.0B | IPO Year: | 2021 |
Target Price: | $23.14 | AVG Volume (30 days): | 353.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.56 | EPS Growth: | N/A |
52 Week Low/High: | $5.58 - $17.79 | Next Earning Date: | 11-12-2024 |
Revenue: | $6,853,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Weinhoff Gregory M | CNTA | Chief Business Officer | Oct 25 '24 | Sell | $15.38 | 11,742 | $180,628.36 | 183,266 | |
SAHA SAURABH | CNTA | Chief Executive Officer | Oct 21 '24 | Sell | $15.59 | 55,000 | $863,727.20 | 663,456 | |
Weinhoff Gregory M | CNTA | Chief Business Officer | Sep 25 '24 | Sell | $15.69 | 16,619 | $260,723.86 | 183,266 | |
SAHA SAURABH | CNTA | Chief Executive Officer | Sep 20 '24 | Sell | $16.53 | 55,000 | $908,985.00 | 663,456 | |
Weinhoff Gregory M | CNTA | Chief Business Officer | Sep 10 '24 | Sell | $17.00 | 30,000 | $510,000.00 | 183,266 | |
Weinhoff Gregory M | CNTA | Chief Business Officer | Sep 9 '24 | Sell | $15.00 | 25,000 | $375,000.00 | 183,266 | |
SAHA SAURABH | CNTA | Chief Executive Officer | Aug 23 '24 | Sell | $12.30 | 46,651 | $573,905.27 | 663,456 | |
Weinhoff Gregory M | CNTA | Chief Business Officer | Aug 22 '24 | Sell | $12.23 | 30,000 | $367,222.06 | 183,266 | |
SAHA SAURABH | CNTA | Chief Executive Officer | Aug 20 '24 | Sell | $12.27 | 8,349 | $102,545.95 | 663,456 |
CNTA Breaking Stock News: Dive into CNTA Ticker-Specific Updates for Smart Investing
MT Newswires
15 hours ago
GlobeNewswire
17 hours ago
GlobeNewswire
9 days ago
MT Newswires
20 days ago
Insider Monkey
a month ago
Insider Monkey
a month ago
GlobeNewswire
2 months ago
MT Newswires
2 months ago
The information presented on this page, "CNTA Centessa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.